Introduction
The Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648) is a highly specific and potent antibody that targets the CD31/PECAM1 protein in humans. This protein is a member of the immunoglobulin superfamily and is expressed on the surface of endothelial cells, platelets, and leukocytes. CD31/PECAM1 plays a crucial role in regulating cell adhesion, migration, and signaling, making it an important target for research and therapeutic applications.
Structure of CD31/PECAM1
CD31/PECAM1 is a transmembrane glycoprotein that consists of six extracellular immunoglobulin-like domains, a transmembrane domain, and a short cytoplasmic tail. The extracellular domains of CD31/PECAM1 are responsible for its interaction with other proteins, while the cytoplasmic tail contains signaling motifs that mediate its cellular functions.
Activity of CD31/PECAM1
CD31/PECAM1 is primarily known for its role in regulating cell adhesion and migration. It is involved in the formation of endothelial cell-cell junctions, which are crucial for maintaining the integrity of blood vessels. CD31/PECAM1 also plays a key role in leukocyte transmigration, where it facilitates the movement of immune cells from the bloodstream into tissues during an inflammatory response.
In addition to its adhesion functions, CD31/PECAM1 also has signaling properties. It can activate intracellular signaling pathways, such as the PI3K/Akt pathway, which is important for cell survival and proliferation. CD31/PECAM1 has also been shown to regulate the activity of other signaling molecules, such as integrins and growth factor receptors, further highlighting its importance in cellular processes.
Application of Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648)
The Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648) has been widely used in research to study the function of CD31/PECAM1 and its role in various biological processes. This antibody has been shown to specifically bind to CD31/PECAM1 and block its activity, making it a valuable tool for studying the protein’s function.
One of the main applications of this antibody is in the field of immunology. CD31/PECAM1 is a key regulator of immune cell trafficking, and the Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648) has been used to study its role in immune cell migration and activation. This antibody has also been used in studies investigating the role of CD31/PECAM1 in inflammatory diseases, such as atherosclerosis and rheumatoid arthritis.
In addition to its research applications, the Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648) has potential therapeutic applications. CD31/PECAM1 has been identified as a potential target for cancer therapy, as it is overexpressed in many types of cancer and plays a role in tumor angiogenesis. The use of this antibody in targeting CD31/PECAM1 could potentially inhibit tumor growth and metastasis.
Conclusion
In summary, the Anti-Human CD31/PECAM1 Monoclonal Antibody (1A648) is a highly specific and potent antibody that targets the CD31/PECAM1 protein. This protein is involved in regulating cell adhesion, migration, and signaling, making it an important target for research and potential therapeutic applications. The use of this antibody has greatly contributed to our understanding of CD31/PECAM1 and its role in various biological processes, and it continues to be a valuable tool in the field of immunology and cancer research.
There are no reviews yet.